pipette
ESEspañol

Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy

Xavier Puéchal, G. Pugnet, Benjamin Thoreau, Claire DE MOREUIL, S. Jouneau, Thomas Quéméneur, Gabriel Baron, P. Smets, Antoine Néel, Thomas Le Gallou, Nicolas Noël, Y. Uzunhan, Chloé Comarmond-Ortoli, G. Urbanski, Y. Benhamou, ALICE BEREZNE, Arsène Mekinian, Mohamed Amine Hamidou, Julien Campagne, Noémie Abisror, Pascal Cohen, Loı̈c Guillevin, Philippe Ravaud, Benjamin Terrier, French Vasculitis Study Group, Elisabeth DIOT, Jonathan London, Paul Legendre, Antoine Dossier, Nicolas SCHLEINITZ, Mikaël EBBO, Achille Aouba, Alexandre Nguyen, Divi Cornec, L. Sailler, Dominique Chauveau, P. Duffau, jean-francois Viallard, Carine Greib, Cécile Durant, Sabine Revuz, F. Maurier, Kim Heang LY, Nicolas Limal, Maxime Samson, Bernard Bonnotte, Eric Oziol, Renaud Felten, Nicolas Girszyn, S. Trad and 10 more

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Conclusions and Relevance For participants with newly diagnosed or relapsing EGPA, rituximab was not superior to azathioprine for improving the duration of total remission during 28 months while taking prednisone at 7.5 mg/d or less.

Appeared: Saturday, October 24. JAMA. Peer-reviewed journal.

DOI: 10.1001/jama.2026.15278